Go Jelly, go
The UK-based pioneer in marine biotechnologies Jellagen has closed a £3.8m funding round to boost sales of its next-generation jellyfish-based medicine. Lead investor were Newable Private Investing and the Development Bank of Wales.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2185 entries already.
Entries by Thomas Gabrielczyk
Irish Iterum files for IPO on Nasdaq
Iterum Therapeutics plans to raise up to US$92m in an initial public offering on US technology stock market Nasdaq. The Irish company develops oral and IV antibiotics for urinary tract infections and intra-abdominal infections.
Near-term capital for Neurimmune
US biotech company Biogen has exercised the option of a one-off payment to Swiss developer Neurimmune. If Biogen’s Alzheimer’s candidate Aducanumab is approved, the sales-related payments to Neurimmune will thus be reduced by 5%.
Diabetes drug reverses PAH
A new study shows that a drug approved for the treatment of diabetes reverses pulmonary arterial hypertension (PAH) and prevents right heart failure in rats. Ekaterina Legchenko and colleagues say their findings could lead to new therapies for PAH and other chronic heart and lung conditions.
Targovax gives pipeline update
Norwegian Targovax ASA has given an update of its immunononcology and pancreatic cancer clinical pipeline at ChinaBio Conference in Suzhou.
Inhibitor-free DNA for increased reliability in PCR analysis
BioEcho GmbH develops kits for the isolation and processing of DNA and RNA with a rapidly expanding portfolio. With expertise and passion, we overcome the limitations of common nucleic acid extraction with pioneering methods such as the proprietary Echolution single-step technology.
AZ’s Durvalumab/Tremelimumab combo flops in NSCLC
British drug maker AstraZeneca has failed to expand the reach of its combo of PD-1/CTLA4 checkpoint blockers Durvalumab/Tremelimumab. The approved second-line NSCLC treatment missed to prolong progression-free and overall survival in patients with low PD-L1 expression.
Palbociclib companion biomarker unraveled
Researchers at the Universities of Dundee and Newcastle have identified a previously unknown target for the breast cancer drug palbociclib, which can be used to identify treatment responders.
GMP and new processes: be prepared for hassle
Poor aseptic practices can rapidly ruin market supply of products outsourced for production. This year, Celltrion came under fire from FDA inspectors. At the end of January, the producer received a warning letter affecting the production of Inflectra biosimilar infliximab-dyyb (CT- P13) co-marketed with Pfizer. In mid-February, the FDA added a warning concerning rituximab and trastuzumab biosimilars produced for Teva, as well as for its fast-track migraine mAb fremanezumab.
GBS 2018: Bioeconomy leaders foster shift to sustainable industry production
International collaboration is needed to secure living of the growing world population without collapse of the planet’s resources, biodiversity and climate. A communique published at the end of the Global Bioeconomy Summit (GBS) outlines policy measures needed to create a biobased economy for all.